NTEK Nothing else matters!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another excellent resource for knowledge on BIEL Gramps! Your videos will one day be looked back as the basis of marketing for BIEL that takes this little company to the BIG TIME!
Keep up the fantastic work Gramps!
People who say it cannot be done should not interrupt those who are doing it. Guess what BIEL is doing it!
And that is coming my friend ! ; )
Thanks but no thanks, this is not kool-aid here this is the reality of a paradigm shift in healing and if you have not used the product for its purpose well your just another voice in the winds of negative BS. Way to many of us here that new back in 2009 that this one was and is something special something actually quite terrific. I could have cared less back then about the money prospect it was the uniqueness of how I and many others found how it reduced pain and healed. So today is quite different and the globe is reaching a new awareness of this technological break through. Support it or look foolish it's that simple this is the next biggest thing since the internet!
Release #:812-172273-rl-799204:
NHS approves a low-level Pulsed ElectroMagnetic Field (PEMF) therapy device for pain relief
The UK’s National Health System (NHS), funded by the government, has approved an application to cover and pay for a low-level PEMF therapy device. The device, manufactured by BioElectronics, uses PEMF technology (also known as Pulsed Short Wave Technology) to provide relief from musculoskeletal pain. NewMed Ltd., the UK’s one-stop-shop for PEMF therapy, hopes this will raise awareness of PEMF therapy and its health benefits.
PEMF therapy is an idea harnessed by NASA which uses the Earth’s magnetic fields in a concentrated manner to provide non-invasive and drug-free pain relief. PEMF therapy stimulates cellular repair to improve your body’s overall performance and has many benefits such as improving recovery time, pain-relief and sleep.
According to data collected from around 140,000 adults over 19 studies, an estimated 43% of people in the UK suffer from chronic pain. A clinical study found that the use of low-level PEMF therapy not only helped to relieve pain, but could also reduce overall healthcare costs by 42% (58.5% reduction in physician appointment costs, 35% reduction in prescription medication costs).
Andy Smith, Sales Director, says:
At NewMed we offer a wide range of devices, including BioElectronics’ Recovery RX, to suit all needs. It is our mission to promote the benefits of PEMF’s through independent and unbiased advice. Over the past 3 years we have been established, we have already helped so many people as seen by their testimonials about PEMF therapy on our website. We aim to continue improving the quality of life for so many across the UK by raising awareness of this innovative therapy and now that PEMF is being used in the NHS we hope that more people will consider this drug-free alternative.
Source:
https://www.newmedltd.co.uk/
(SOME) people don't realize Andy's track record does speak for itself you could not have said it better and thank you for that! What he has been able to do on a minuscule budget has kept this company intact and successful finally as a result with tons more to come. Andy can be held accountable for what has taken place and I could not be more pleased with where the results have finally taken us and a little DD through the years has confirmed that for me physically (ActiPatch user) and from a share holder perspective for 9 years.
Portland, OR....BIEL ActiPatch user since 2009! Heals my Dog too!
This article has direct link to the Federal Register to post comments for the upcoming Patient-Focused Drug Development on Chronic Pain; Public Meeting on July 9th at 10am. Excellent chance to give focus to BIEL and use of the ActiPatch. The more awareness the sooner it becomes a pain away mainstay!
https://www.painnewsnetwork.org/stories/2018/5/14/fda-commissioner-listening-to-pain-patients
https://www.federalregister.gov/documents/2018/05/15/2018-10284/patient-focused-drug-development-on-chronic-pain-public-meeting-request-for-comments
FDA is particularly interested in hearing from patients who experience chronic pain that is managed with analgesic medications such as opioids, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants; other medications; and non-pharmacologic interventions or therapies.
This article has direct link to the Federal Register to post comments for the upcoming Patient-Focused Drug Development on Chronic Pain; Public Meeting on July 9th at 10am. Excellent chance to give focus to BIEL and use of the ActiPatch. The more awareness the sooner it becomes a pain away mainstay!
https://www.painnewsnetwork.org/stories/2018/5/14/fda-commissioner-listening-to-pain-patients
https://www.federalregister.gov/documents/2018/05/15/2018-10284/patient-focused-drug-development-on-chronic-pain-public-meeting-request-for-comments
FDA is particularly interested in hearing from patients who experience chronic pain that is managed with analgesic medications such as opioids, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants; other medications; and non-pharmacologic interventions or therapies.
Trump appointing Dr. Oz to his sport, fitness and nutrition council.
And guess who has seen, touched and used the ActiPatch on their show ???
connecting the dots ...just sayin
https://www.cnn.com/2018/05/04/politics/trump-dr-oz-health-advisor/index.html
So this is what takes place when an ActiPatch is used over an animals (Our Husky named Devon) incision where a 10 lb. tumor was removed. April 19th was day of surgery and today with the wrap removed as witnessed in the pictures a vastly different healing of the wound area's with and without. The top of his back and down around his side shows how much difference with the ActiPatch in place. The skin and fur both has grown in significantly faster within 10 days. Pictures don't lie! Go Biel !
So this is what takes place when an ActiPatch is used over an animals (Our Husky named Devon) incision where a 10 lb. tumor was removed. April 19th was day of surgery and today with the wrap removed as witnessed in the pictures a vastly different healing of the wound area's with and without. The top of his back and down around his side shows how much difference with the ActiPatch in place. The skin and fur both has grown in significantly faster within 10 days. Pictures don't lie! Go Biel ! Sorry Tinypic.com seems to be down I will try to upload pictures in a different format!
Nice present day capture of current BIEL info srinsocal! I can't think of a better moment in BIEL history that I have witnessed so many paths of this products potential. I continue to see progress here in the U.S. and have high hopes to add to your list will be the application of the ActiPatch in our military and veteran health care. I believe those discussions are at BIEL's doorstep!
Well said Simps! The companies that survive longest are the ones that work out what they uniquely can give to the world not just growth or money but their excellence, and in BIELS case their ability to heal people! Since 2009 for me using the ActiPatch was a life changer to my mobility and daily functions. Today the cascade of changes taking place with the placement of BIEL's products worldwide completely suffocates the "need to know" theory and it is revealing itself with every passing week. It couldn't be more obvious today where we are going! The Tsunami warning sirens around the world are going off more and more each day!
Gramps your Vid's get better each time. Confident that your contributions have already helped the bottom line. Excellent job your work is much appreciated!
Awesome job Gramps! No doubt your timing is impeccable to carry the word as momentum is building. I am sharing this with several I network with that are deep pockets for BIEL already. Your link will multiply, excellent job!
Seven I like your thinking! I have often thought the right conditions needed to be in place for something like this to happen. The condition is the epidemic of drugs and pain medications that have become so abused. The legislative hearings both past and present no doubt can and will endorse the technology that BioElectronics has masterfully patented and delivered!
I believe we are on that edge as well! People ...watch and learn! ; )
Most excellent point Simps! I have always looked at the Allay as being revolutionary in managing menstrual pain. The is nothing else like it in the world for treating this type of most common female human ailment. Staggering to think what its potential is becoming and could very well can be the most substantial consistent revenue for BIEL in the near future.
You don't need to tell me.....I know when!
Excellent find fbsf32 ! The world is waking up to reality and change is necessary to adapt and move forward in health care EVERYWHERE! The UK is leading the way and the ActiPatch has a means to be such a huge answer.
Are we not glad, we who have tried and used the product glad to be here on this board knowing what the future holds!
GO BIEL !
New pain therapy ActiPatch launches in CARE Pharmacies
E & E Communications <pknopick@eandecommunications.com>
Reply|
Today, 10:16 AM
Release #:812-168852-rl-799204:
BioElectronics earlier this month launched its ActiPatch musculoskeletal pain therapy medical device through the regional chain CARE Pharmacies.
“With the current opioid crisis here in the United States, as pharmacists, we are delighted to be able to address the dire need for a safe over-the-counter alternative to opioids. Our focused pain consultations will enhance our patients’ relationships,” Mark Ey, vice president operations at CARE, said. “Providing therapeutic patient care is what we are trained to do.”
Pain sufferers and their physicians and pharmacists dramatically need an alternative first line therapy for pain. “We look forward to working with the CARE Pharmacies’ pharmacists to provide better safer patient care,” said Keith Nalepka, vice president sales and marketing at the Frederick, Md.-based BioElectronics.
New research shows that pain persists because the nerves have “learned” pain. When this happens, the body become rcs highly sensitive to pain signals that do not go away even after the injury has healed. ActiPatch’s technology, first introduced into the U.S. market last year, reaches deep into the painful area to safely disrupt the abnormal pain signals, the company noted.
1/18/2018 1:13:18 PM 799204
Simps you have always had the vision here no matter how disgruntled and frustrated longs have been and I for one appreciate all your contributions to this board! I have never doubted BIEL would become a game changer and paradigm shift one day and I think the shift is now taking place with yesterdays UK NHS announcement. I bought and tried my first ActiPatch back in 2009 and to watch the evolution of the product has been incredible not to mention results which sealed it for me as an investor. We are not at a crossroads anymore we have crossed the road and from here on its going to be some unbelievable growth. What can be said ! Your post captured it and could not be better said!
I used to post here a lot to contradict naysayers. There's no need for that much anymore it's been approved it's going forward. Attempts to contradict now are futile , looking forward to the future of this product there is nothing like it.
Opioids reduced life expectancy, Not the case with ActiPatch it may prove to even increase life expectancy reducing chronic pain one day.
http://www.cnn.com/2017/09/19/health/opioids-life-expectancy-study/index.html
Raise the Bar BIEL....Gov. Chris Christie leads Trump panel on opioid crisis
1 minute ago
The live event has ended
From the White House:
President's Commission on Combating Drug Addiction and Opioid Crisis
The Commission is established in the interest of obtaining advice and recommendations for the President regarding the opioid crisis. The Commission functions solely as an advisory body and makes recommendations regarding policies and practices for combating drug addiction with particular focus on the current opioid crisis in the United States.
The Commission's objectives are to:
a. identify and describe the existing Federal funding used to combat drug addiction and the opioid crisis.
b. assess the availability and accessibility of drug addiction treatment services and overdose reversal throughout the country and identify areas that are underserved.
c. identify and report on best practices for addiction prevention, including healthcare provider education and evaluation of prescription practices, collaboration between State and Federal officials, and the use and effectiveness of State prescription drug monitoring programs.
d. review the literature evaluating the effectiveness of educational messages for youth and adults with respect to prescription and illicit opioid.
e. identify and evaluate existing Federal programs to prevent and treat drug addiction for their scope and effectiveness, and make recommendations for improving these programs.
f. make recommendations to the President for improving the Federal response to drug addiction and the opioid crisis.
Try telling Andy that the patents are the only thing of value. Have been here since 2009 using the product when and if I was able to get one which led me to put my money where the pain was. Typically when one misses the opportunity it comes out in the posting. We are on the cusp of a new product revolutionary and unknown. Yes 6 months from now the value of the patent will have one up tremendously along with chasing the pps. Know what you own!
Why are you stating no big investors interested? We've only been across the fence for a little over a month. Premature statement with no evidence right?
Heard the same thing back in 2009 buying my first shares. If I had listened I would have missed the most recent boatload of green that brought my ship in closer. The best is yet to come, the hardest part of proof has been proven. PEMF works just ask my knees!
FREDERICK, MD--(Marketwired - Feb 28, 2017) - BioElectronics Corporation (OTC PINK: BIEL)
The following is a statement by BioElectronics Corporation President Andrew J. Whelan:
Dear Fellow Shareholders,
US FDA Over-the Counter Market Clearance
The US FDA has now cleared ActiPatch for over-the-counter sales for the adjunctive treatment of musculoskeletal pain related to: (1) heel pain and (2) osteoarthritis of the knee.
We would have preferred an even broader clearance, but this is a great start. We have an ongoing back pain study in progress at the Oxford University Hospital that should suffice to obtain a broader market clearance in the near future.
Immediate Objectives
BioElectronics Corporation is well poised to capture the paradigm shift in medicine towards electroceuticals. The Company's immediate objectives are:
1. Enter a License and Supply Agreement with a major OTC marketing partner. We seek a partner that has boots on the ground and the managerial and financial resources to execute immediate worldwide retail market penetration. We believe the recent US FDA over-the-counter clearances coupled with the following make us very attractive to major consumer health product companies:
Impressive Efficacy of ActiPatch: 65% of subjects attain a 57% VAS pain score reduction allowing a good night's rest, restoration of daily activities, and an improved quality of life. Safety profile of ActiPatch: No reported adverse events, no side effects. ActiPatch's ability to help mitigate the opioid addiction epidemic: surveys that indicate our customers on average have a 50% Reduction in Medication Use, including opioids. ActiPatch's Exceptional Consumer Acceptance and Demonstrated Marketability: We have developed an innovative approach on how to market an OTC disposable medical device to consumers. The Company's Try & Tell Sales and Marketing Campaign won the OTC Bulletin "Best OTC Marketing Campaign on a Small Budget" award. Since current chronic pain therapies do not meet the need for chronic pain relief, pain sufferers are skeptical of new products. To overcome this skepticism and accelerate product acceptance, we promote and sell a discounted 7-Day Trial ActiPatch device for $9.95 without an on/off switch. Of the trial users, 58% purchased the 720-hour retail units for $30.00, with an average purchase of 1.7 devices within 90 days and 2.7 devices over 1 year.
2. Obtain reimbursement clearance from the National Health System in the UK and Canada. Recently we received a request for additional information on the cost benefit of ActiPatch from the NHS in the UK.
3. Complete the development and testing of the extra strength prescription post-operative chronic wound care device.
4. Complete the clinical trial for back pain at Oxford University Hospital and conduct the migraine headache study. The R&D team has put together a protocol to investigate the efficacy of the ActiPatch in preventing the onset of migraine attacks and/or reducing pain during an attack. The protocol was submitted to Binghamton University's IRB and is awaiting approval. The study will commence in March 2017 and is expected to be completed in June 2017.
This research effort is a collaboration between BioElectronics Corporation, Binghamton University and Eppley Plastic Surgery. Dr. Ken McLeod, from Binghamton University is the principal investigator and a pioneer researcher in the world of bioelectromagnetics. Dr. Barry Eppley, from Eppley Plastic Surgery is a co-investigator and has years of experience treating chronic migraines. Dr. Ian Rawe and Dr. Sree Koneru, both from BioElectronics Corporation, are co-investigators and bring in their clinical and engineering research expertise respectively.
5. Expand clinical evidence on the use of ActiPatch in lieu of or for the reduction of opioids or other narcotics.
6. Continue to seek out international distribution partners. Recently we entered agreements for Lebanon, Bangladesh, and Thailand.
On behalf of the entire staff of BioElectronics, I want to thank all you for your faith in the future of our Company. Please be sure you have "liked" ActiPatch on Facebook and share our posts with your friends and family. You can also let friends and family know that our products can be ordered at www.tryactipatch.com and via Amazon.
Sincerely,
Andrew J. Whelan
President
Contact Information
BioElectronics Corporation
Paul Knopick
940-262-3584
ir@bielcorp.com
My EANDE
More Information
This statement has been what drew me to this product long before I invested in it!
There is no "competitive technology" to ActiPatch for effective, low-cost, adjunctive wound care.
Colorofmoney has been a pillar of information on BIEL for years considered a mentor of ActiPatch information. His post(s) is never more accurate. This technology is a stand alone in the market right now years ahead of any other compitition. I have always know since investing here since 2009 that FDA approval is typically what connects the dots universally worldwide to get buy in to leverage this rocket off the launch pad. Launch is now successful first stage booster about to release! Investors will be orbiting millions here and I'm one of the strongest Bielievers here since using the product for years !
Ha, your dead wrong I've been using this therapy since 2011 and works magnificent on my knee. I've passed on ActiPatch to twelve other users of which 10 have continued to find its use very effective. Don't for a minute think this is not effective pain treatment! 90% users are return users!
Love it Simps! Been here a long time and just sayin your contributions of DD has kept me as a BIELiever! I haven't sold a share! Now the fun begins, appreciate all you bring to the board!
Agree with you UK, and yes my similar experience using the product told me I never give up on this one! Guess what to the rest of them, WE TOLD YOU SO!
BioElectronics President Interviewed by the StockRadio.com Discusses BioElectronics, the Science of the Chronic Pain market, and Drug Use
Mr. Whelan explained the science of bioelectronics, the chronic pain market, the far-reaching product portfolio, and its award winning "Best OTC Marketing Campaign on a Small Budget"
FREDERICK, MD--(Marketwired - Oct 27, 2016) - BioElectronics Corporation (OTC PINK: BIEL), the maker of advanced nonprescription disposable $30.00 neuromodulation pain relief medical devices, is pleased to release an interview with President, Andy Whelan. The interview can be heard at http://westbrookradio.com/2016/10/26/andrew-whelan-ceo-bioelectronics-corp-biel/
Mr. Whelan explained the science of bioelectronics, the chronic pain market, the far-reaching product portfolio, its award winning "Best OTC Marketing Campaign on a Small Budget," and its assessment of 12,000+ users and the exceptional product acceptance.
Chronic Pain - 20% of adults globally suffers from chronic pain. This market is larger than diabetes, heart disease, and cancer combined. ActiPatch is a nonprescription medical device that addresses the unmet need for 1.5 billion chronic pain sufferers worldwide that modifies the way the central nervous system works. The modification results in an increase in pain perception from less provocation. ActiPatch modulates the body's nerve activity to dampen the pain perception, thereby mitigating the use of drugs. Kenneth McLeod, Ph.D. Director of Clinical Science and Engineering Research, New York State University Binghamton's short video explains how the technology and ActiPatch work at http://actipatch.com/why-actipatch/.
Demonstrated Marketability to Consumers - The Company's Try and Tell sales and marketing campaign has won this year's OTC Bulletin "Best OTC Marketing Campaign on a Small Budget"award. ActiPatch therapy is the leading analgesic in Walgreens/Boots in the UK.
Current chronic pain therapies do not meet the need for chronic pain relief and sufferers are skeptical. To overcome the skepticism and accelerate product acceptance, we promote a discounted 7-Day Trial device without an on/off switch. 65% of testers averaged a 57% reduction in pain and said they "intended" to or would "maybe" purchase. 80% did purchase an average of 1.75 devices within 90-days. After one year, the users purchased an average of 2.7 devices.
A leading pain management medical journal Pain Management published a 5,000+ subject study: A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35. The data demonstrates a consistent clinically meaningful effect in chronic musculoskeletal pain from a variety of causes (osteoarthritis, rheumatoid arthritis, fibromyalgia, post-surgical, neuropathic) affecting different regions of the body (back, hip, knee, wrist, elbow, and shoulder).
Additionally, our 6 month Observation Study demonstrates:
Treatment durability: Over 90% of the participants reported continued relief averaging a 61% reduction in pain even after six months.Decreased medication use: 86% reported a decrease in medication use that continued to improve over time. Most importantly, this decrease included prescription narcotic based drugs.Improved quality of life: 90% reported improved sleep, 89% reported greater physical activity, and 71% reported their quality of life was much better to a great deal better.Healthcare savings: 65% spent less on pain therapies and 65% reported fewer visits to the doctor and pain specialist.Decreased adverse events from medication use: 68% were experiencing adverse side effects, of these 71% reported a reduction in adverse side effects.Side effects: None reported
US FDA OTC Market Clearance - The Company has submitted a 510(k) pre market application to the FDA with three ActiPatch randomized clinical trials. Additionally, the clinical trials evidence is being supplemented with a Registry of a 5,600 consumer assessment on back pain, a 6-Month Observational Study on product durability, a Medication Use Reduction Study and a Sleep Improvement Study.
Mr. Whelan also explained the technology's significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation, and other applications.
About BioElectronics Corporation
BioElectronics Corporation is the maker of a leading family of affordable, disposable, drug-free, medical devices. ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; HealFast® Therapy and the Allay® Menstrual Pain Therapy. Please visit www.bielcorp.com for clinical evidence and a video on how it works.
CONTACT INFORMATION
Grace Holdings, Inc.
732-335-1152
EdTWhelan@BIELCorp.com
Used my knee ActiPatch last night. Woke up to near 90% pain free today, what more proof do you need? Been here loooong time buddy validation was proved loooong ago for me!
Impressive video? NOT! I hope you purchase of those units and get soaked for that price. Crazy especially when I have used the ActiPatch and it truly works well!
BioElectronics Engages Adam Staelin As Executive Vice President of Sales and Marketing
[11-May-2016]
FREDERICK, Md., May 11, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer pain management medical devices, today announced that it has engaged Adam Staelin as the Executive Vice President of Sales and Marketing.
Mr. Staelin has 20 years of sales and marketing experience and has held major management roles at Teradata and Valassis. While at Teradata, a provider of solutions and services in data warehousing, analytics, and marketing applications, he led the marketing development of a key customer application. At Valassis, a provider of direct mail media and marketing services across the US, Canada, and Mexico, he was co-responsible for a four branch, 90 sales representatives and 140 million dollar sales region. Mr. Staelin has a BA in Psychology and an MBA from the Duke University Fuqua School of Business.
"We are excited to have Adam join our Company. His wealth of experience in sales and marketing will have an immediate impact on international sales and our US sales launch," said Andrew Whelan, President of BioElectronics.
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Contact:
Grace Holdings
732 335 1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-engages-adam-staelin-as-executive-vice-president-of-sales-and-marketing-300266552.html
SOURCE BioElectronics Corporation
Web Site: http://www.bioelectronicscorp.com
-- PH95512 --
05/11/2016 08:37 EDT
Hmmmm interesting that forward predictions by NFLX regards the disruptive technology competition as a concern. Why did I move portion of my position here to UF ?! The telling answer is in the future of television!
I'm not pushing anything, let the technology stand on its own. Both companies have disruptive technology and that's what I'm comparing. Share price means nothing at this point.